This study is comparing two ways to reduce bleeding risk in patients who have had a stent placed in their heart (percutaneous coronary intervention or PCI) due to coronary artery disease. After PCI, patients typically take two antiplatelet medicines (dual antiplatelet therapy or DAPT) like aspirin and prasugrel or ticagrelor. This trial looks at whether reducing the dose of prasugrel (from 10 mg to 5 mg) or switching from a stronger antiplatelet to a weaker one (clopidogrel 75 mg) is more effective at preventing blood clots while lowering bleeding risk. The main goal is to measure how well platelets are working after about a month. You may be able to join if you are 18 or older, have had PCI, and are currently taking aspirin with either prasugrel (10 mg) or ticagrelor (90 mg). The study plans to enroll 78 participants, but its current status is unclear.

Study design

This is an interventional study comparing two different antiplatelet treatments. It plans to enroll 78 participants.

What's involved

Participants will take either clopidogrel 75 mg or prasugrel 5 mg once daily for 30 ± 5 days. Platelet reactivity will be measured at the end of this period.

Compensation

Not stated in the trial record.

Follow-up

Platelet reactivity will be measured at 30 ± 5 days after starting the study medication.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.